Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis

Urology. 2020 Jun:140:7-13. doi: 10.1016/j.urology.2020.03.007. Epub 2020 Mar 19.

Abstract

We performed a systematic review to examine the efficacy and outcomes of Botulinum Toxin A (BoNT-A) as the primary intervention strategy for patients with detrusor external sphincter dyssynergia. Eleven studies were included in the analysis (n = 353; 16% female, 84% male). BoNT-A was effective in 60%-78% of patients for reducing postvoid residual, mean detrusor pressure, detrusor leak point pressure, and mean urethral pressure 1 month after injection. Most patients required reinjection after an average of 4-9 months. BoNT-A was not associated with any significant adverse events, and may improve quality of life, as well as urodynamic parameters for detrusor external sphincter dyssynergia.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adult
  • Anal Canal*
  • Anus Diseases / drug therapy*
  • Anus Diseases / physiopathology
  • Ataxia / drug therapy*
  • Ataxia / physiopathology
  • Botulinum Toxins, Type A / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / therapeutic use*
  • Prospective Studies
  • Quality of Life
  • Retreatment
  • Retrospective Studies
  • Treatment Outcome
  • Urethra / drug effects
  • Urethra / physiopathology

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A
  • incobotulinumtoxinA